BTIG Reiterates Buy Rating on Oruka Therapeutics, Keeps $151 Target
BTIG reiterated its Buy rating and $151 price target on Oruka Therapeutics. The target implies 109.9% upside from the stock’s Oct. 16 close of $71.93.
BTIG reiterated its Buy rating and $151 price target on Oruka Therapeutics. The target implies 109.9% upside from the stock’s Oct. 16 close of $71.93.